PE20020853A1 - Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas - Google Patents

Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas

Info

Publication number
PE20020853A1
PE20020853A1 PE2002000061A PE2002000061A PE20020853A1 PE 20020853 A1 PE20020853 A1 PE 20020853A1 PE 2002000061 A PE2002000061 A PE 2002000061A PE 2002000061 A PE2002000061 A PE 2002000061A PE 20020853 A1 PE20020853 A1 PE 20020853A1
Authority
PE
Peru
Prior art keywords
alkyl
epotilones
heterocycle
methods
pharmaceutical compositions
Prior art date
Application number
PE2002000061A
Other languages
English (en)
Inventor
Rebanta Bandyopadhyay
Krishnaswamy Srinivas Raghavan
Sailesh Amilal Varia
Timothy M Malloy
Andrea Panaggio
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20020853A1 publication Critical patent/PE20020853A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN METODO PARA AUMENTAR LA BIODISPONIBILIDAD DE EPOTILONOS DE FORMULA I, II, ADMINISTRADOS ORALMENTE; DONDE G ES ALQUILO, ARIL, HETEROCICLO; R8HC=C(R9)-, DR10HC-; (R11)(R12)N-C(O)-, W ES O, NR16; X ES O, S, CHR17, H, R18; Y ES H, H; H, OR22; OR23, OR23; NOR24; NOR25, NHNR28R29, NHNR30, CHR32, ENTRE OTROS; B1 Y B2 SON H, OR33, OCOR34; OCONR35R36, NR37R38; D ES NR42R43, HETEROCICLO; R1, R2, R3, R4, R5 SON H, ALQUILO; R8, R9, R10, R11 SON H, ALQUILO, ARIL, CICLOALQUILO, HETEROCICLO; R17, R18, R22, R23 SON H, ALQUILO; R24, R25, R26, R28, R30, R32, R33, R34, R35, R36, R37, R39, R40, R41, R42, R51, R52, R53, R61 SON H, ALQUILO, ARIL; R12, R16, R27, R29, R31, R38, R43 SON H, ALQUILO, ARIL, CICLOALQUILO, HETEROCICLO, R51, CO; R52OCO, R53SO2, HIDROXI, O-ALQUILO Y UN BUFFER TAL COMO FOSFATO DE SODIO DIBASICO ANHIDRO, DIHIDRATO CITRATO DE SODIO, ACIDO CITRICO ANHIDRO CON UN pH DE 5 A 9 SIENDO EL SOLVENTE RECONSTITUYENTE UNA MEZCLA DE PROPILENGLICOL Y ETANOL. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE DE 0,05mg A 200mg DE EPOTILONO, BUFFER. UN COMPUESTO PREFERIDO [1S-[1R*,3R*(E),7R*,10S*,11R*,16S*]]-7,11-DIHIDROXI-8,8,10,12,16-PENTAETIL-3-[1-METIL-2-(2-METIL-4-TIAZOL)ETENIL-17-OXA-4-AZABICICLO[14.1.0]HEPTADECANO-5,9-DIONA
PE2002000061A 2001-01-25 2002-01-25 Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas PE20020853A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29001901P 2001-05-11 2001-05-11

Publications (1)

Publication Number Publication Date
PE20020853A1 true PE20020853A1 (es) 2002-09-27

Family

ID=26950349

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000061A PE20020853A1 (es) 2001-01-25 2002-01-25 Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas

Country Status (26)

Country Link
US (2) US6576651B2 (es)
EP (1) EP1361877A1 (es)
JP (1) JP2004528287A (es)
KR (1) KR20040025888A (es)
CN (1) CN1268336C (es)
AR (1) AR035078A1 (es)
BG (1) BG108027A (es)
BR (1) BR0206695A (es)
CA (1) CA2434584A1 (es)
CZ (1) CZ20032023A3 (es)
EE (1) EE200300329A (es)
HR (1) HRP20030674A2 (es)
HU (1) HUP0303800A3 (es)
IL (1) IL156759A0 (es)
IS (1) IS6892A (es)
MX (1) MXPA03006476A (es)
NO (1) NO20033343L (es)
NZ (1) NZ526871A (es)
PE (1) PE20020853A1 (es)
PL (1) PL368636A1 (es)
RU (1) RU2291695C2 (es)
SK (1) SK9212003A3 (es)
TW (1) TWI250017B (es)
UY (1) UY27138A1 (es)
WO (2) WO2002058699A1 (es)
YU (1) YU58103A (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
KR100804873B1 (ko) 1999-06-10 2008-02-20 얼라이드시그날 인코퍼레이티드 포토리소그래피용 ｓｏｇ 반사방지 코팅
US6824879B2 (en) 1999-06-10 2004-11-30 Honeywell International Inc. Spin-on-glass anti-reflective coatings for photolithography
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
PL367260A1 (en) * 2001-01-25 2005-02-21 Bristol-Myers Squibb Company Parenteral formulation containing epothilone analogs
CN1774253A (zh) 2001-02-20 2006-05-17 布里斯托尔-迈尔斯斯奎布公司 用环氧丙酯酮衍生物治疗顽固性肿瘤
SK11082003A3 (sk) * 2001-03-14 2004-08-03 Bristol-Myers Squibb Company Kombinácia analógov epotilónu a chemoterapeutických činidiel na liečenie proliferatívnych ochorení
CN1606713B (zh) 2001-11-15 2011-07-06 霍尼韦尔国际公司 用于照相平版印刷术的旋涂抗反射涂料
US7211593B2 (en) * 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1551425A4 (en) * 2002-10-09 2006-09-20 Kosan Biosciences Inc THERAPEUTIC FORMULATIONS
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EA012798B1 (ru) * 2003-08-26 2009-12-30 Шир Холдингз Аг Фармацевтический состав, содержащий карбонат лантана (варианты)
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
CA2545806C (en) 2003-11-14 2014-09-16 Brigham And Women's Hospital, Inc. Methods of modulating immunity
US8053159B2 (en) 2003-11-18 2011-11-08 Honeywell International Inc. Antireflective coatings for via fill and photolithography applications and methods of preparation thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20060069136A1 (en) * 2004-09-24 2006-03-30 Ulrich Klar Use of Epothilones in the treatment of bone metastasis
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
PL1817013T3 (pl) * 2004-11-18 2009-01-30 Bristol Myers Squibb Co Dojelitowa powlekana peletka zawierająca Ixabepilone
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8642246B2 (en) 2007-02-26 2014-02-04 Honeywell International Inc. Compositions, coatings and films for tri-layer patterning applications and methods of preparation thereof
PL2276485T3 (pl) 2008-04-24 2014-12-31 Bristol Myers Squibb Co Stosowanie epotilonu D w leczeniu chorób związanych z Tau, w tym choroby Alzheimera
US8557877B2 (en) 2009-06-10 2013-10-15 Honeywell International Inc. Anti-reflective coatings for optically transparent substrates
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US8864898B2 (en) 2011-05-31 2014-10-21 Honeywell International Inc. Coating formulations for optical elements
CN102276433B (zh) * 2011-06-30 2016-04-20 南昌大学 木豆素c及其衍生物及其在制备抗癌药物中的应用
US10544329B2 (en) 2015-04-13 2020-01-28 Honeywell International Inc. Polysiloxane formulations and coatings for optoelectronic applications

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
ATE249463T1 (de) 1995-11-17 2003-09-15 Biotechnolog Forschung Gmbh Epothilonderivate, herstellung und verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
PT932399E (pt) * 1996-03-12 2006-05-31 Pg Txl Co Lp Pro-farmacos de paclitaxel hidrossoluveis
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) * 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
EP1367057B1 (de) 1996-11-18 2008-09-17 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilone E und F
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
HU228851B1 (en) 1997-02-25 2013-06-28 Biotechnolog Forschung Gmbh Process for preparing epothilones with a modified side chain and compounds prepared by this process
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja) 1997-04-18 2008-03-26 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ATE224882T1 (de) 1997-07-16 2002-10-15 Schering Ag Thiazolderivate, verfahren zur herstellung und verwendung
DK1005465T3 (da) 1997-08-09 2007-11-05 Bayer Schering Pharma Ag Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
NZ506389A (en) 1998-02-05 2003-07-25 Novartis Ag Pharmaceutical compositions containing epothilone which can be optionally lyophilised
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
ATE307123T1 (de) 1998-02-25 2005-11-15 Sloan Kettering Inst Cancer Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
HUP0105478A3 (en) 1999-02-18 2002-08-28 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
PL207720B1 (pl) 2001-01-25 2011-01-31 Bristol Myers Squibb Co Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej
SK11082003A3 (sk) 2001-03-14 2004-08-03 Bristol-Myers Squibb Company Kombinácia analógov epotilónu a chemoterapeutických činidiel na liečenie proliferatívnych ochorení

Also Published As

Publication number Publication date
KR20040025888A (ko) 2004-03-26
USRE40387E1 (en) 2008-06-17
NZ526871A (en) 2006-01-27
IL156759A0 (en) 2004-02-08
EP1361877A1 (en) 2003-11-19
NO20033343L (no) 2003-09-24
UY27138A1 (es) 2002-08-30
RU2291695C2 (ru) 2007-01-20
CZ20032023A3 (cs) 2005-03-16
CN1498106A (zh) 2004-05-19
WO2002058699A1 (en) 2002-08-01
RU2003126174A (ru) 2005-02-27
TWI250017B (en) 2006-03-01
BR0206695A (pt) 2004-04-20
YU58103A (sh) 2006-03-03
AR035078A1 (es) 2004-04-14
US20020177615A1 (en) 2002-11-28
NO20033343D0 (no) 2003-07-24
CA2434584A1 (en) 2002-08-01
BG108027A (bg) 2004-12-30
HUP0303800A2 (hu) 2004-03-29
IS6892A (is) 2003-07-24
HUP0303800A3 (en) 2005-02-28
AU2002253880B2 (en) 2006-11-09
MXPA03006476A (es) 2003-09-22
US6576651B2 (en) 2003-06-10
PL368636A1 (en) 2005-04-04
HRP20030674A2 (en) 2005-06-30
JP2004528287A (ja) 2004-09-16
WO2002058701A1 (en) 2002-08-01
EE200300329A (et) 2003-10-15
CN1268336C (zh) 2006-08-09
SK9212003A3 (en) 2004-11-03

Similar Documents

Publication Publication Date Title
PE20020853A1 (es) Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas
KR100884575B1 (ko) 미노시클린 함유 조성물
US4701320A (en) Composition stably containing minocycline for treating periodontal diseases
ES2620413T3 (es) Formulaciones veterinarias antihelmínticas tópicas
EP1782816B1 (en) Water-based medicinal composition containing azithromycin and method of preparing the same
ES2096781T3 (es) Composiciones de oxicodones de liberacion controlada.
RS49566B (sr) Kompozicije koje sadrže antifungicidno sredstvo i acetatni pufer
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
JPH0597668A (ja) 歯周炎の治療
ES2381672T3 (es) Preparación en solución acuosa que comprende un antibiótico aminoglicósido y bromfenaco
MX2007006635A (es) Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
MEP10808A (en) Solid drug for oral use
ME00467B (me) 13-točlani azalidi i njihova primena kao antibiotičkih sredstava
HUP0103431A2 (hu) 5-HT4 receptor agonista vagy antagonista hatóanyagot tartalmazó, orális gyógyászati készítmény
HU230738B1 (hu) Ketotifén tartalmú szemészeti készítmény
CZ281599B6 (cs) Farmaceutické prostředky s obsahem ranitidinu
NO912414L (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
JP4799957B2 (ja) 口内炎の治療のための医薬組成物
AR024411A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo[2.2.2]oct-3-ilamina y sus composiciones farmaceuticas.
ES2197781B1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
RU2678821C1 (ru) Фармацевтическая композиция для лечения заболеваний полости рта с противовоспалительным и антибактериальным действиями
MX9803275A (es) Composiciones farmaceuticas que contienen inhibidores de agregacion de plaquetas.
JPH0234325B2 (ja) Shishushitsukanchiryoyososeibutsu
WO2022244968A1 (ko) 벤지다민염산염을 포함하는 안정성이 개선된 가글액

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed